111 related articles for article (PubMed ID: 3822287)
21. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
[TBL] [Abstract][Full Text] [Related]
22. Occult bilateral involvement in stage I epithelial ovarian cancer.
Benjamin I; Morgan MA; Rubin SC
Gynecol Oncol; 1999 Mar; 72(3):288-91. PubMed ID: 10053097
[TBL] [Abstract][Full Text] [Related]
23. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
24. [Appendix cancer].
Blauensteiner W; Armbruster C; Kriwanek S; Tuchmann A
Zentralbl Chir; 1990; 115(1):61-2. PubMed ID: 2156395
[No Abstract] [Full Text] [Related]
25. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
27. Effect of surgical debulking on survival in stage IV ovarian cancer.
Liu PC; Benjamin I; Morgan MA; King SA; Mikuta JJ; Rubin SC
Gynecol Oncol; 1997 Jan; 64(1):4-8. PubMed ID: 8995539
[TBL] [Abstract][Full Text] [Related]
28. Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience.
Pham TH; Wolff B; Abraham SC; Drelichman E
Ann Surg Oncol; 2006 Mar; 13(3):370-6. PubMed ID: 16485156
[TBL] [Abstract][Full Text] [Related]
29. Depth of invasion for appendiceal metastasis of ovarian cancers: does it have any clinical significance?
Ayhan A; Gultekin M; Sağlam EA; Dursun P; Dogan NU; Aksan G; Usubutun A; Yuce K
J Obstet Gynaecol Res; 2008 Aug; 34(4):557-60. PubMed ID: 18937709
[TBL] [Abstract][Full Text] [Related]
30. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer.
Guidozzi F; Ball JH
Gynecol Oncol; 1994 Jun; 53(3):326-30. PubMed ID: 8206406
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Gagetti O; Prontera C; Bianchi R; Facchini V
Gynecol Oncol; 1995 Aug; 58(2):184-8. PubMed ID: 7542621
[TBL] [Abstract][Full Text] [Related]
32. Is appendicectomy mandatory in patients with ovarian carcinoma?
Sonnendecker EW
S Afr Med J; 1982 Dec; 62(26):978-80. PubMed ID: 7147144
[TBL] [Abstract][Full Text] [Related]
33. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
34. Management of early-stage epithelial ovarian cancer.
Benjamin I; Rubin SC
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):107-19. PubMed ID: 8015759
[TBL] [Abstract][Full Text] [Related]
35. Routine appendectomy in extensive gynecologic operations.
Westermann C; Mann WJ; Chumas J; Rochelson B; Stone ML
Surg Gynecol Obstet; 1986 Apr; 162(4):307-12. PubMed ID: 3961652
[TBL] [Abstract][Full Text] [Related]
36. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
[TBL] [Abstract][Full Text] [Related]
37. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.
Bristow RE; Lagasse LD; Karlan BY
Cancer; 1996 Nov; 78(10):2049-62. PubMed ID: 8918397
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
Munkarah AR; Hallum AV; Morris M; Burke TW; Levenback C; Atkinson EN; Wharton JT; Gershenson DM
Gynecol Oncol; 1997 Jan; 64(1):13-7. PubMed ID: 8995541
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of second cytoreductive surgery in the treatment of epithelial ovarian cancer.
Sun T; Feng Y
Chin Med J (Engl); 1998 Mar; 111(3):272-4. PubMed ID: 10374433
[TBL] [Abstract][Full Text] [Related]
40. Endometriosis of the appendix.
Duinslaeger M; Goovaerts G; De Waele B; Willems G
Acta Chir Belg; 1985; 85(4):219-21. PubMed ID: 4050252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
